Otic & Eledon
pharma & biotech
pharma & biotech

Otic Pharma was founded at Peregrine Ventures’ Incentive Incubator, where it developed a foam-based drug-delivery platform for the treatment of ear, nose and throat disorders.

In 2017, Otic Pharma merged with Nasdaq-listed Tokai Pharmaceuticals, providing Peregrine with a public-market exit. The resulting public company was later renamed Eledon Pharmaceuticals (Nasdaq: ELDN).